Samrakshan: An Indian Radiological and Imaging Association program to reduce perinatal mortality in India

Abstract

Context: India has a high perinatal mortality rate. The Indian Radiological and Imaging Association (IRIA) is supplementing efforts to address perinatal mortality in India through the Samrakshan program. Aims: To describe various elements of the Samrakshan program that aims to reduce perinatal mortality in India. Methods: Samrakshan focuses on two priority areas, preeclampsia (PE) and fetal growth restriction (FGR). Samrakshan aims at technical skill upgradation, specifically focused on improved interpretative ability, prognostic and therapeutic efficacy using Doppler studies, a free online learning platform and offline continuous medical educations (CMEs), building an evidence base from the program to develop policy and guidelines, and improving synergy with the RAKSHA program of IRIA and other fetal care stakeholders. Results: Two courses on Doppler studies focused on first trimester and third trimester, supplemented by case discussions and journal articles, have started on the online platform with 230 registrants. The first statewide CME was held at Indore. Samrakshan screening identified 10 (17.24%, 95% CI: 8.59, 29.43) women at high risk for preterm PE and 29 (50.00%, 95% CI 36.58, 63.42) women at high risk for FGR in the first trimester. Ten fetuses (7.63%, 95% CI: 3.72, 13.59) including 9 with stage 1 FGR were identified in the third-trimester screening. Conclusions: Samrakshan is a flagship program of IRIA that aims to reduce perinatal mortality in India through a synergistic, holistic approach that complements and supplements existing efforts in India.

Keywords

Doppler ultrasound - fetal growth restriction - India - perinatal mortality - preeclampsia - screening

Publikationsverlauf

Eingereicht: 18. September 2019

Angenommen: 25. September 2019

Artikel online veröffentlicht:
21. Juli 2021

• References

• 1 International Institute for Population Sciences (IIPS) and ICF. National Family Health Survey (NFHS-4) 2015-16. India. Mumbai: IIPS; 2017
• 2 Million Death Study Collaborators. Bassani DG, Kumar R, Awasthi S, Morris SK, Paul VK, Shet A. et al. Causes of neonatal and child mortality in India: A nationally representative mortality survey. Lancet 2010; 376: 1853-60
• 3 Niti Ayog, India. Maternal Mortality Ratio (per 100,000 live births). Available from: https://www.niti.gov.in/content/maternal-mortality-ratio-mmr-100000-live-births. [Last accessed on 2019 Sep 02]
• 4 Tan MY, Syngelaki A, Poon LC, Rolnik DL, O’Gorman N, Delgado JL. et al. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation. Ultrasound Obstet Gynecol 2018; 52: 186-95
• 5 Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C. et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377: 613-22
• 6 Litwinska M, Syngelaki A, Wright A, Wright D, Nicolaides KH. Management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks’ gestation. Ultrasound Obstet Gynecol 2018; 52: 365-72
• 7 Panaitescu A, Ciobanu A, Syngelaki A, Wright A, Wright D, Nicolaides KH. Screening for preeclampsia at 35–37 weeks’ gestation. Ultrasound Obstet Gynecol 2018; 52: 501-6
• 8 Figueras F, Gratacós E. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther 2014; 36: 86-98
• 9 Malik A, Jee B, Gupta SK. Preeclampsia: Disease biology and burden, its management strategies with reference to India. Pregnancy Hypertens 2019; 15: 23-31
• 10 Ghossein-Doha C, van Neer J, Wissink B, Breetveld NM, de Windt LJ, van Dijk AP. et al. Pre-eclampsia: An important risk factor for asymptomatic heart failure. Ultrasound Obstet Gynecol 2017; 49: 143-9
• 11 Sharma D, Sharma P, Shastri S. Genetic, metabolic and endocrine aspect of intrauterine growth restriction: An update. J Matern Fetal Neonatal Med 2017; 30: 2263-75
• 12 Sharma D, Shastri S, Sharma P. Intrauterine growth restriction: Antenatal and postnatal aspects. Clin Med Insights Pediatr 2016; 10: 67-83
• 13 Sharma D, Farahbakhsh N, Shastri S, Sharma P. Intrauterine growth restriction-Part 2. J Matern Fetal Neonatal Med 2016; 29: 4037-48
• 14 Sharma D, Shastri S, Farahbakhsh N, Sharma P. Intrauterine growth restriction-Part 1. J Matern Fetal Neonatal Med 2016; 29: 3977-87
• 15 Khadilkar AV, Parthasarathy LS. Fetal growth restriction and cardiovascular health among adolescents. Indian Pediatr 2015; 52: 107-8
• 16 O’Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, de Alvarado M. et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation: Comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol 2017; 49: 756-60
• 17 Sotiriadis A, Hernandez-Andrade E, da Silva Costa F, Ghi T, Glanc P, Khalil A. et al. ISUOG practice guidelines: Role of ultrasound in screening for and follow-up of pre-eclampsia. Ultrasound Obstet Gynecol 2019; 53: 7-22
• 18 Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D. et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: Results of SPREE. Ultrasound Obstet Gynecol 2018; 51: 743-50
• 19 Poon LC, Rolnik DL, Tan MY, Delgado JL, Tsokaki T, Akolekar R. et al. ASPRE trial: Incidence of preterm pre-eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm. Ultrasound Obstet Gynecol 2018; 51: 738-42